ARS Pharmaceuticals annual depreciation and amortization
2020
2021
2022
2023
2024
2025
ARS Pharmaceuticals Depreciation & Amortization Growth & History (SPRY)
ARS Pharmaceuticals's depreciation and amortization was $1.4M for fiscal 2025.
View full ARS Pharmaceuticals company overviewARS Pharmaceuticals annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.4M | $1.3M | +1630.38% |
| 2024 | 2024-12-31 | $79,000 | −$21,000 | −21.00% |
| 2023 | 2023-12-31 | $100,000 | −$219,000 | −68.65% |
| 2022 | 2022-12-31 | $319,000 | $106,000 | +49.77% |
| 2021 | 2021-12-31 | $213,000 | −$424,000 | −66.56% |
| 2020 | 2020-12-31 | $637,000 | — | — |
ARS Pharmaceuticals quarterly depreciation and amortization
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $416,000 | $137,000 | +49.10% |
| Q1 2026 | 2026-03-31 | $397,000 | $117,000 | +41.79% |
| Q4 2025 | 2025-12-31 | −$586,000 | — | — |
| Q3 2025 | 2025-09-30 | $391,000 | $291,000 | +291.00% |
| Q2 2025 | 2025-06-30 | $279,000 | $261,000 | +1450.00% |
| Q1 2025 | 2025-03-31 | $280,000 | $269,000 | +2445.45% |
| Q3 2024 | 2024-09-30 | $100,000 | $0 | 0.00% |
| Q2 2024 | 2024-06-30 | $18,000 | −$2,000 | −10.00% |
| Q1 2024 | 2024-03-31 | $11,000 | −$9,000 | −45.00% |
| Q3 2023 | 2023-09-30 | $100,000 | $93,000 | +1328.57% |
| Q2 2023 | 2023-06-30 | $20,000 | — | — |
| Q1 2023 | 2023-03-31 | $20,000 | −$187,000 | −90.34% |
| Q3 2022 | 2022-09-30 | $7,000 | −$194,000 | −96.52% |
| Q1 2022 | 2022-03-31 | $207,000 | $20,000 | +10.70% |
| Q3 2021 | 2021-09-30 | $201,000 | $30,000 | +17.54% |
| Q2 2021 | 2021-06-30 | $209,000 | $71,000 | +51.45% |
| Q1 2021 | 2021-03-31 | $187,000 | $48,000 | +34.53% |
| Q3 2020 | 2020-09-30 | $171,000 | — | — |
| Q2 2020 | 2020-06-30 | $138,000 | — | — |
| Q1 2020 | 2020-03-31 | $139,000 | — | — |
ARS Pharmaceuticals depreciation and amortization trends
Over the last five fiscal years, ARS Pharmaceuticals's depreciation and amortization increased from $637,000 to $1.4M, a change of $730,000. The latest reported quarter, Q2 2026, shows $416,000.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review ARS Pharmaceuticals source filings ↗